Journal of Clinical Oncology
Articles in this Issue
p53 pathway genes' mutations as prognostic factors in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center study.
771 Background: Mutations (muts) in oncosuppressor genes have been associated with poor prognosis in different solid tumors. This study aims to evaluate t...
Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review.
528 Background: Liver cancer continues to be a significant public health concern, particularly among high-risk groups such as individuals with hepatitis i...
AGITG SPAR: A randomized, placebo-controlled, phase II trial of simvastatin in addition to neoadjuvant chemotherapy and radiation for rectal cancer.
141 Background: Retrospective clinical studies and preclinical studies demonstrated that statin use during preoperative (chemo)radiation (pCRT) for rectal...
Effects of the delay of surgery in localized rectal cancer.
63 Background: The treatment landscape for localized rectal cancer has evolved significantly in recent years, with long-course neoadjuvant chemoradiation...
Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
208 Background: The use of total neoadjuvant therapy is now standard of care and is favored when treating locally advanced rectal cancer but its treatment...
Young onset gastrointestinal cancer: A needs analysis.
383 Background: The global incidence of Young Onset ( YO) cancers diagnosed in adults under 50 years, is increasing for unknown reasons. YO Gastrointestin...
Impact of race on end-of-life care among patients with esophageal cancer.
337 Background: Esophageal cancer is an aggressive malignancy with rising incidence globally. Patients with advanced esophageal cancer suffer from a heavy...
Hepatotoxicity following external radiotherapy in patients with hepatocellular carcinoma treated with or without prior yttrium-90 radioembolization.
564 Background: A variety of local therapy options exist to treat Hepatocellular Carcinoma (HCC) including external radiotherapy (EBRT). Prior yttrium-90...
Real-world insights into immune-related adverse events (irAE) in gastrointestinal (GI) malignancies.
545 Background: This retrospective review aimed to examine the incidence and baseline characteristics (BLC) that irAE risk in patients with gastrointestin...
Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.
608 Background: Tinengotinib, a spectrum-selective multi-kinase inhibitor with unique binding properties to FGFR , potently inhibi...
Real-world data of durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: A Thailand multicenter observational study.
607 Background: Currently, durvalumab plus gemcitabine and cisplatin is a standard of care for patients with advanced biliary tract cancer (BTC). We aimed...
Non-cancer-related deaths in patients with resectable locally advanced esophageal squamous cell carcinoma: A supplementary analysis of JCOG1109.
434 Background: Neoadjuvant docetaxel, cisplatin, and 5-FU (DCF) has become the standard treatment for resectable locally advanced esophageal squamous cel...
Phase II single-arm, single-center clinical trial of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer.
TPS324 Background: A critical clinical challenge in microsatellite stable (MSS) metastatic colorectal (mCRC) patients is to identify strategies to overcom...
Machine learning–based liquid biomarker analysis from the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) gemcitabine/nab-paclitaxel in resectable PDAC (rPDAC).
755 Background: The phase II NEONAX trial examined PO and A gemcitabine/nab-paclitaxel (G/nP) efficacy for rPDAC pts with a comprehensive biomarker progra...
Personalised use of repurposed non-anticancer drugs in colorectal cancer based on up-regulated signalling pathways: A real world cohort feasibility study.
833 Background: Targeting signaling pathways in colorectal cancers is a common therapeutic strategy. In addition to targeted drugs, non- anticancer drugs...
Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies.
449 Background: A major limitation of CAR-T in solid tumors has been the inability to safely target antigens shared between healthy and malignant tissue....
Comparison of demographics, mortality outcomes and resource utilization in early-onset versus later-onset pancreatic cancer: An analysis of the US National Inpatient Sample (NIS).
700 Background: Pancreatic cancer is associated with higher mortality, with 5-year relative survival of 12%. Early-onset pancreatic cancer (EOPC) is relat...
BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.
16 Background: Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON p...
Hepatocellular carcinoma: A 30-year trend analysis of global burden stratified by risk factors, and socio-demographic indexes.
529 Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related morbidity and mortality worldwide, driven primarily by chronic in...
Focusing on clinical trial ineligibility: Nivolumab plus chemotherapy for patients with advanced gastric cancer.
355 Background: Nivolumab demonstrates promising efficacy when combined with chemotherapy as first-line treatment in patients with advanced gastric cancer...
A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET).
652 Background: There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastro...
A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with <i>KRAS</i> G12C–mutated metastatic colorectal cancer (CodeBreaK 301).
TPS326 Background: CodeBreaK 300 (NCT05198934) evaluated sotorasib, a selective inhibitor that irreversibly binds to the Kirsten rat sarcoma (...
Prognosis of signet ring cell (SRC) gastric carcinoma (GC) compared with other histological subtypes.
357 Background: Signet ring cell (SRC) gastric cancer (GC) has its unique clinicopathological features with poor tissue differentiation, high invasiveness...
Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.
724 Background: RMC-9805 is a potent, oral, RAS(ON) G12D-selective, covalent, tri-complex inhibitor targeting the active,...
Prognosis of patients with liver single-organ metastases: Updated survival results of BBCAPX-II.
157 Background: Although immunotherapy has changed the treatment strategy for many cancers with great success, patients with microsatellite stable (MSS) a...